Pubdate: Wed, 02 Feb 2000 Source: Australian, The (Australia) Copyright: News Limited 2000 Contact: http://www.theaustralian.com.au/ Author: Francesca Hodge HEROIN USERS MISS SUBSIDY ON NALTREXONE AUSTRALIA'S first anti-craving treatment for alcoholics became available on the pharmaceutical benefits scheme from yesterday. Alcoholics will pay $20 for a month's supply of naltrexone but heroin addicts will continue to pay the wholesale price. Distributor Orphan Australia dropped the price of naitrexone on non-PBS private prescriptions from $160 to $144.50 last week but admits it will be almost impossible to secure a subsidy for heroin users. Naltrexone works by blocking opiod receptors in the brain, decreasing the reward sensation and diminishing the need for continued drug use. Orphan's managing director, Alastair Young, said the slight drop in price for privately prescribed naltrexone would put pressure on pharmacists to reduce their mark-up. He said some had charged up to $330 for a month's supply since naltrexone became available on private prescription last year. Orphan would consider asking the Pharmaceutital Benefits Advisory Committee to reconsider PBS listing of naltrexone to heroin addicts. "They (PBAC) have made it incredibly difficult for us," he said. "It will be almost impossible to satisfy their requirements." Perth naltrexone doctor George O'Neil could not be reached for comment but he has been a vocal critic of the decision to make heroin addicts pay full price for the treatment. Stephen Jurd, director of drug and alcohol services at Royal North Shore Hospital in Sydney, said naltrexone was the first of a class of anti-craving drugs that decreased the relapse rate among people with alcohol dependency. The drug, which will be sold under the brandname ReVia, has been shown to prevent relapse, reduce craving and increase abstinence when it is used in conjunction with a treatment program. Alcohol dependence contributes to the deaths of 6000 people in Australia a year. - --- MAP posted-by: Allan Wilkinson